Literature DB >> 19327233

Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

F Oliviero1, P Sfriso, G Baldo, J-M Dayer, S Giunco, A Scanu, D Bernardi, R Ramonda, M Plebani, L Punzi.   

Abstract

OBJECTIVE: To investigate lipid and apolipoprotein (Apo) levels in synovial fluid (SF) and serum of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and osteoarthritis (OA).
METHODS: SF of 44 patients (14 RA, 14 PsA, 16 OA) was tested for Apo A-I, HDL-C, total cholesterol (TC), IL-1Beta, TNF-alpha, white blood cell count (WBC) and polymorphonucleate (PMN) percentage. Blood samples, collected simultaneously to the SF, were examined for Apo A-I, HDL-C, TC, TNF-alpha, serum amyloid A (SAA) and C-reactive protein (CRP). Thirty-three healthy donors served as a control group.
RESULTS: Serum levels of Apo A-I, HDL-C and TC were higher in OA as compared with RA, PsA and the control group. The patients with inflammatory arthritis had lower serum levels of Apo A-I and HDL-C than did the controls. Apo A-I concentrations were higher in SF of RA patients, while PsA showed the highest concentration of TC, though not reaching statistical significance. A negative correlation was found between serum Apo A-I and synovial WBC (r=-0.48 p=0.002) and IL-1Beta (r=-0.42 p=0.016). There was a strong positive correlation between the Apo A-I SF/serum ratio and synovial WBC (r=0.73 p<0.001), IL-1Beta (r=0.68 p<0.001) and a weak, yet significant, correlation with serum CRP (r=0.49 p=0.002) and SAA (r=0.41 p=0.008).
CONCLUSION: Our study confirms that in RA Apo A-I and TC levels are decreased in plasma and increased in SF, thus suggesting infiltration of HDL particles in the inflamed joint with inhibition of the local production of proinflammatory cytokines. On the other hand, it can be hypothesized that the sequestration of Apo A-I in the inflamed tissue may, in part, account for the reduction of circulating HDL and the excess cardiovascular risk in RA and PsA patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327233

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  22 in total

1.  High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritis.

Authors:  Christina Charles-Schoeman; David Meriwether; Yuen Yin Lee; Ani Shahbazian; Srinivasa T Reddy
Journal:  Clin Rheumatol       Date:  2017-11-11       Impact factor: 2.980

2.  Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis.

Authors:  Li-Hao Huang; Bernd H Zinselmeyer; Chih-Hao Chang; Brian T Saunders; Andrew Elvington; Osamu Baba; Thomas J Broekelmann; Lina Qi; Joseph S Rueve; Melody A Swartz; Brian S Kim; Robert P Mecham; Helge Wiig; Michael J Thomas; Mary G Sorci-Thomas; Gwendalyn J Randolph
Journal:  Cell Metab       Date:  2018-11-08       Impact factor: 27.287

3.  Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.

Authors:  Luisa Costa; Francesco Caso; Mariangela Atteno; Antonio Del Puente; Md Abud Darda; Paolo Caso; Augusta Ortolan; Ugo Fiocco; Roberta Ramonda; Leonardo Punzi; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2014-06       Impact factor: 2.980

Review 4.  Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy.

Authors:  Nicola Maruotti; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2014-11-27       Impact factor: 3.984

5.  Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.

Authors:  S Pérez-Baos; J I Barrasa; P Gratal; A Larrañaga-Vera; I Prieto-Potin; G Herrero-Beaumont; R Largo
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

6.  Apolipoprotein a-I at the interface of vascular inflammation and arthritis.

Authors:  Robert Terkeltaub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03       Impact factor: 8.311

Review 7.  Metabolic syndrome meets osteoarthritis.

Authors:  Qi Zhuo; Wei Yang; Jiying Chen; Yan Wang
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

8.  High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals.

Authors:  Anna Scanu; Francesca Oliviero; Lyssia Gruaz; Paolo Sfriso; Assunta Pozzuoli; Federica Frezzato; Carlo Agostini; Danielle Burger; Leonardo Punzi
Journal:  Arthritis Res Ther       Date:  2010-02-11       Impact factor: 5.156

Review 9.  Lipid disturbances in psoriasis: an update.

Authors:  Aldona Pietrzak; Anna Michalak-Stoma; Grazyna Chodorowska; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

10.  Cardiovascular risk in patients with psoriatic arthritis.

Authors:  Tracy Y Zhu; Edmund K Li; Lai-Shan Tam
Journal:  Int J Rheumatol       Date:  2012-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.